Stocks › N › NDRM

NeuroDerm's (NDRM) — Earnings Call X-Ray

Our AI read all 5 of NDRM's earnings calls (2016–2017) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q4 2016 · sign up to see
Previous Call Grade
C
Q3 2016
Expected Move
🔒
next 45 days · members
Calls Analyzed
5
2016–2017
Avg Candor
6.2/9
evasion 3.4/9
Guidance RaisedPromotional ToneCritic AmmunitionMargins ContractingCapex IncreasingReads RehearsedQuestion Left HangingResults Worse Than Direction

Call-by-call analysis

🔒 Q4 2016 earnings call 2017-03-30 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor ■/9
Specificity ■/9
Evasion ■/9
Stress ■/9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q4 2016 call grade is ready
The full 37-point AI read of NDRM's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

C Q3 2016 earnings call 2016-11-10

Management raised guidance against contracting margins. The delivery was rich in specifics, promotional in tone.

Guidance: raisedMargins: contractingHeadcount: growingCapex: increasing 2 analysts · 3 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable⚑ Reads rehearsedDirection beats results
Candor 6/9
Specificity 7/9
Evasion 4/9
Confidence 8/9
Uncertainty 3/9
Promotion 7/9
Stress 2/9
Complexity 5/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

B+ Q2 2016 earnings call 2016-08-25

Management lowered guidance against contracting margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: loweredMargins: contractingPricing: not applicableHeadcount: growing 4 analysts · 12 questions
✓ Clean call✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubtsDirection beats results
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 8/9
Uncertainty 3/9
Promotion 6/9
Stress 1/9
Complexity 5/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
NO Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

C Q1 2016 earnings call 2016-05-26

Management held guidance steady against contracting margins. The delivery was rich in specifics.

Guidance: maintainedMargins: contracting 3 analysts · 6 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsedDirection beats results
Candor 6/9
Specificity 7/9
Evasion 3/9
Confidence 7/9
Uncertainty 4/9
Promotion 5/9
Stress 2/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

D Q4 2015 earnings call 2016-03-31

Management held guidance steady. The delivery was rich in specifics.

Guidance: maintainedHeadcount: growing 3 analysts · 5 questions
⚑ Critic ammunition⚑ Question left hanging✓ Guidance underwritable⚑ Reads rehearsed
Candor 6/9
Specificity 7/9
Evasion 4/9
Confidence 7/9
Uncertainty 3/9
Promotion 4/9
Stress 2/9
Complexity 6/9
All 20 questions our AI answered about this call
NO Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
NO Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAP · Advance Auto Parts, Inc.ABCAF · Athabasca Minerals, Inc.ABDC · Alcentra Capital'sABMD · Abiomed, Inc.ABNRY · ABN AMRO Bank N.V.ABOS · Acumen Pharmaceuticals,

← NDRBF   All “N” companies    NDSN →

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.